Growth hormone decreases protein catabolism in children with cystic fibrosis.

What Was Tested

Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this randomized controlled trial publication.

The purpose of this report is to summarize their findings of the effect of GH on whole body protein kinetics in cystic fibrosis and to relate these findings to changes in TNF-alpha levels.

Why It Was Studied

Despite aggressive nutritional therapy, low body weight and protein catabolism are common problems in children with cystic fibrosis.

Baseline results from the subjects with cystic fibrosis were compared with results obtained from nine age- and gender-matched healthy children.

Who Took Part

According to the abstract, 19 children were involved.

PubMed indexes the participants as children, both men and women.

How the Study Was Run

The researchers set it up as a randomized study.

The children were allocated by chance, so the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group should start out alike.

Whole body protein turnover was measured at baseline and every 6 months using the stable isotope [1-(13)C]leucine and mass spectrometric analysis.

What Was Measured

Topics PubMed links to this paper include Algorithms, Body Height, Cystic Fibrosis, Dietary Proteins, Growth Hormone, Insulin and Insulin-Like Growth Factor I.

What This Means in Plain Language

The paper is a randomized study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 19 children.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2001 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.